Syndax Pharmaceuticals Reports Second Quarter 2022 Financial Results and Provides Clinical and Business Update

/PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical-stage biopharmaceutical company developing an...

Related Keywords

Keitha Goldan ,Sharon Klahre ,Michaela Metzger ,Company On Twitter ,Linkedin ,Syndax Pharmaceuticals ,Drug Administration ,Leukemia Lymphoma Society ,Nasdaq ,Exchange Commission ,International Number ,Lymphoma Group ,Prnewswire Syndax Pharmaceuticals Inc ,Syndax Pharmaceuticals Inc ,Chief Executive ,Pipeline Progress ,New Drug Application ,Lymphoma Society ,Master Clinical ,Australasian Leukaemia ,Clinical Trial ,Lee Symptom Scale ,Biologics License Application ,Chief Financial ,Dial In Number ,Private Securities Litigation Reform Act ,Months Ended June ,Nc ,